ICER calls out three drugs from BMS and Lil­ly in re­port on un­sup­port­ed price in­creas­es in Cal­i­for­nia

Drug pric­ing watch­dog ICER on Thurs­day re­leased its fi­nal re­port on drug price in­creas­es in Cal­i­for­nia that were un­sup­port­ed by new clin­i­cal ev­i­dence, point­ing to three out­liers — Bris­tol My­ers Squibb’s can­cer drugs Revlim­id and Spry­cel, and Eli Lil­ly’s mi­graine drug Em­gal­i­ty.

The re­port builds on a price trans­paren­cy law passed in Cal­i­for­nia in 2017, which re­quires man­u­fac­tur­ers to re­port year-over-year spend­ing in­creas­es to pre­scrip­tion drugs’ WAC prices, but does not in­clude net prices, which ICER took is­sue with.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER